- Home
- FIHL vs VERA Comparison
FIHL vs VERA Comparison
Compare FIHL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- VERA
- Stock Information
- Founded
- FIHL 2014
- VERA 2016
- Country
- FIHL Bermuda
- VERA United States
- Employees
- FIHL N/A
- VERA N/A
- Industry
- FIHL
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- FIHL
- VERA Health Care
- Exchange
- FIHL Nasdaq
- VERA Nasdaq
- Market Cap
- FIHL 2.1B
- VERA 2.5B
- IPO Year
- FIHL 2023
- VERA 2021
- Fundamental
- Price
- FIHL $17.43
- VERA $42.01
- Analyst Decision
- FIHL Buy
- VERA Strong Buy
- Analyst Count
- FIHL 9
- VERA 9
- Target Price
- FIHL $20.50
- VERA $53.56
- AVG Volume (30 Days)
- FIHL 302.1K
- VERA 683.6K
- Earning Date
- FIHL 11-12-2024
- VERA 11-07-2024
- Dividend Yield
- FIHL 2.30%
- VERA N/A
- EPS Growth
- FIHL N/A
- VERA N/A
- EPS
- FIHL 3.82
- VERA N/A
- Revenue
- FIHL $2,151,300,000.00
- VERA N/A
- Revenue This Year
- FIHL N/A
- VERA N/A
- Revenue Next Year
- FIHL $13.62
- VERA N/A
- P/E Ratio
- FIHL $4.55
- VERA N/A
- Revenue Growth
- FIHL N/A
- VERA N/A
- 52 Week Low
- FIHL $11.55
- VERA $9.68
- 52 Week High
- FIHL $20.53
- VERA $50.78
- Technical
- Relative Strength Index (RSI)
- FIHL 46.22
- VERA 52.57
- Support Level
- FIHL $17.24
- VERA $39.22
- Resistance Level
- FIHL $17.74
- VERA $50.00
- Average True Range (ATR)
- FIHL 0.34
- VERA 2.41
- MACD
- FIHL -0.04
- VERA 0.24
- Stochastic Oscillator
- FIHL 28.79
- VERA 28.53
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a global (re)insurance company. It classify the business into three underwriting segments, namely Bespoke, Specialty and Reinsurance. Specialty primarily comprises property D&F, energy, marine and aviation lines. Bespoke primarily comprises credit and political risk and other tailored solutions for clients including transactional liabilities and credit insurance. Reinsurance primarily comprises property reinsurance.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.